GoodRx Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $785.2M-0.9% YoYTTM through 30 Jun 2026
Net Income $16.2M-0.9% YoYTTM through 30 Jun 2026
Free Cash Flow $197.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 92.8% |
| EBITDA Margin | 20.8% |
| Operating Margin | 11.0% |
| Net Margin | 2.1% |
Returns
4.9%ROE
2.2%ROA
1.9%ROIC
Balance Sheet Health
Debt / Equity0.80x
Current Ratio2.61x
Net Debt$233.2M
Cash & Equivalents$296.1M
Quality Metrics
Altman Z-Score0.25
Piotroski F-Score5 / 9
FCF Margin25.1%
Rule of 4026.8
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $796.9M
Diluted EPS$0.06TTMFY2025: $0.09
Dividend
No dividend
Capital Allocation
R&D Spend$116.8M
Capex Intensity0.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Prescription Transactions | $544M | -5.8% | |
| Pharma Direct | $151.4M | +41.2% | View detailsManagement expects at least 30% growth in 2026. |
| Subscriptions | $83.8M | -3.1% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.